The average one-year price target for Palvella Therapeutics (NasdaqCM:PVLA) has been revised to $178.50 / share. This is an increase of 33.50% from the prior estimate of $133.70 dated December 3, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $91.91 to a high of $214.20 / share. The average price target represents an increase of 78.98% from the latest reported closing price of $99.73 / share.
What is the Fund Sentiment?
There are 164 funds or institutions reporting positions in Palvella Therapeutics. This is an increase of 47 owner(s) or 40.17% in the last quarter. Average portfolio weight of all funds dedicated to PVLA is 0.14%, an increase of 17.36%. Total shares owned by institutions increased in the last three months by 42.67% to 8,940K shares. 
The put/call ratio of PVLA is 0.53, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,161K shares representing 9.81% ownership of the company. In its prior filing, the firm reported owning 697K shares , representing an increase of 40.02%. The firm increased its portfolio allocation in PVLA by 426.12% over the last quarter.
Suvretta Capital Management holds 822K shares representing 6.95% ownership of the company. In its prior filing, the firm reported owning 714K shares , representing an increase of 13.12%. The firm increased its portfolio allocation in PVLA by 171.83% over the last quarter.
Frazier Life Sciences Management holds 722K shares representing 6.10% ownership of the company. No change in the last quarter.
First Light Asset Management holds 542K shares representing 4.58% ownership of the company.
Perceptive Advisors holds 395K shares representing 3.34% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
